 The protocol MC-FludT.17M is a clinical phase II trial to describe the safety and efficacy of Treosulfan-based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation allo-HSCT in at least 70 paediatric patients with haematological malignancies male and female children with haematological malignant diseases as acute lymphoblastic leukaemias ALL, acute myeloid leukaemias AML, myelodysplastic syndromes MDS and juvenile myelomonocytic leukaemias JMML, requiring myeloablative conditioning treatment with following allo-HSCT. 